

- Infertility (*Cont.*):  
 approach to the patient, 2388  
 chemotherapy-related, 103e-25–26, 623  
 in congenital adrenal hyperplasia, 2356  
 in cystic fibrosis, 1697  
 definition of, 2387  
 etiology of, 2387–2388, 2388f  
 in Klinefelter's syndrome, 2350–2351  
 male, 2360, 2388, 2388f, 2389, 2725  
 menstrual disorders and, 2388. *See also*  
 Menstrual disorders  
 ovulatory dysfunction/failure in, 336–337,  
 437, 2388, 2389  
 prevalence of, 2254t, 2387  
 psychological aspects of, 2388  
 screening/testing for, 2254t  
 STIs causing, 870t  
 treatment of, 2388–2389  
 tubal disease and, 2388, 2389  
 in Turner's syndrome, 2352
- Infestations  
 delusional, 2750–2751  
 fly, 2746–2747  
 leech, 2747  
 louse, 2745–2746  
 maggot, 2747  
 scabies, 2744–2745  
 tongue worms, 2747
- Inflamming, 94e-4
- Inflammasome(s)  
 characteristics of, 372e-1, 372e-4  
 diseases associated with, 372e-8t, 1845, 2215  
 gut microbiota and, 86e-8  
 in response to infection, 145e-7, 145e-8f, 1752
- Inflammation  
 aging and, 75, 75f, 76, 94e-4  
 anemia and, 398, 628, 628t  
 in asthma, 1672–1673, 1672f  
 atherosclerosis and, 291e-2, 291e-9, 291e-9f  
 cardinal signs of, 414f  
 chronic, 145e-10  
 endothelium in, 265e-2  
 immune cells at sites of, 372e-28f  
 nociceptor-induced, 88  
 phagocyte activation and, 145e-5  
 trafficking molecules in, 372e-29t  
 in vivo assessment of, 423
- Inflammatory bowel disease (IBD), **1947**. *See also*  
*Crohn's disease*; *Ulcerative colitis*  
 after infectious diarrhea, 855t  
 in ankylosing spondylitis, 2171  
 atypical colitides mimicking, 1957  
 cancer risk in, 1965  
 colorectal cancer in, 539, 1898t, 1964–1965,  
 1964f  
 commensal microbiota and, 1948f, 1949  
 differential diagnosis of, 1061, 1956–1957  
 disorders associated with, 1949t, 2178–2179  
 dysplasia in, 1964f, 1965  
 early-onset, 1949, 1949t  
 epidemiology of, 1947, 1947t  
 etiology of, 1947–1948, 1947f  
 extraintestinal manifestations of  
 aortitis, 1642  
 cardiopulmonary, 1959  
 dermatologic, 369, 1956–1957  
 hepatobiliary, 1958  
 metabolic bone disorders, 1958  
 neuropathy, 2683  
 ocular, 1958  
 oral, 237  
 rheumatologic, 1958  
 thromboembolic disorders, 1958  
 urologic, 1958  
 genetic considerations in, 1947, 1948f, 1949,  
 1949t, 1950t  
 global considerations in, 1947  
 gut microbiota and, 86e-8  
 immune regulation in, 372e-27t, 1949–1950  
 inflammatory cascade in, 1950–1951  
 noninfectious diseases mimicking, 1957  
 pathogenesis of, 1948–1950, 1948f  
 in pregnancy, 49, 1964  
 racial and ethnic differences in, 1947–1948
- smoking and, 1947  
 in spondyloarthritis, 2178–2179  
 treatment of, **1959**, 1963f  
 antibiotics, 1960  
 5-ASA agents, 1959–1960, 1959t  
 azathioprine, 1960  
 biologic therapies, 1961  
 cyclosporine, 1960–1961  
 glucocorticoids, 1960  
 6-mercaptopurine, 1960  
 methotrexate, 1960  
 nutritional therapies, 1960  
 during pregnancy, 1964  
 surgery, 1962–1964, 1963t  
 tacrolimus, 1961  
 therapies in development, 1962  
 tumor markers in, 473t
- Inflammatory diarrhea, 269–270. *See also*  
 Diarrhea
- Inflammatory mediators, in sensitization, 87–88
- Inflammatory myopathies. *See also*  
 Dermatomyositis; *Inclusion body*  
 myositis; *Polymyositis*  
 autoantibodies in, 2196  
 clinical features of, 2194–2195, 2195t  
 diagnosis of, 2199–2200, 2199t  
 differential diagnosis of, 2195t, 2197–2199  
 drug-induced, 462e-20, 2197, 2199  
 global considerations in, 2197  
 malignancies associated with, 2196  
 overlap syndrome, 2196  
 pathogenesis of, 2196–2197, 2197f, 2198f  
 prognosis of, 2202  
 treatment of, 2200–2202
- Inflammatory response, 1746–1747, 1747f,  
 1950–1951
- Infliximab  
 adverse effects of  
 actinomycosis, 1088  
 common, 2146t  
 cutaneous, 377  
 infections, 422, 1962  
 septic arthritis, 834  
 serious, 348t, 1962, 2146t  
 for ankylosing spondylitis, 2172–2173, 2172f  
 antibodies to, 1961  
 for autoimmune and inflammatory diseases,  
 372e-30  
 for IBD, 1961, 2179  
 monitoring during treatment with, 2146t  
 for psoriatic arthritis, 348t, 2177  
 for rheumatoid arthritis, 2145, 2146t  
 for sarcoidosis, 2211–2212, 2212t
- Influenza, **1209**  
 asthenia following, 1212  
 in cancer patient, 489  
 clinical features of, 784, 1202t, 1211–1212  
 complications of, 1211, 1211t, 1212–1213  
 control of, 916–917  
 deaths from, 6e-1t, 56t  
 definition of, 1209  
 diagnosis of, 775, 1213  
 epidemiology of, 778, 1209–1211  
 extrapulmonary complications of, 1212–1213  
 laryngitis in, 234  
 monocyte dysfunction in, 422  
 morbidity and mortality caused by, 1211  
 myocarditis in, 1560  
 otitis media in, 229  
 pandemic and inter-pandemic disease patterns  
 and features, 1209t, 1210  
 pathogenesis of, 1211  
 pathogen evolution of, 778, 1209–1210, 1209t  
 pharyngitis in, 231  
 pneumonia and, 1212  
 in pregnancy, 50, 1212  
 prevention of, 215e-2t, 215e-5, 1213t, 1214.  
*See also* Influenza vaccine  
 Reye's syndrome and, 1212–1213  
 sinusitis in, 226  
 in transplant recipient, 923  
 treatment of, 214e-5–6, 215e-1, 215e-2t,  
 215e-5–6, 1213–1214, 1213t  
 in upper respiratory infections, 225
- Influenza A viruses, 1209–1211, 1209f, 1209t  
 Influenza B viruses, 1209, 1211  
 Influenza C viruses, 1209, 1211  
 Influenza vaccine  
 contraindications to, 789t, 1213  
 coverage in U.S., 792  
 Guillain-Barré syndrome and, 1214, 2695  
 inactivated, 789t, 1214  
 live attenuated, 789t, 1214  
 precautions for, 789t  
 recommended administration of  
 in adults, 29t, 84, 787f, 788f, 809, 1214  
 in cancer patients, 485t, 492  
 in HIV infection, 798, 1252t  
 in liver disease, 1995  
 in pregnancy, 50  
 in transplant recipients, 929t  
 in travelers, 794
- Influenza virus  
 adherence of, 145e-2t  
 as bioterrorism agent, 261e-9  
 cell membrane interactions of, 214e-3  
 host range of, 214e-6  
 mutations in, 214e-5  
 subtypes of, 1209t  
 viral assembly and egress in, 214e-5  
 virology of, 1209
- Information technology, 3
- Informed consent, 4, 17e-1, 443, 449
- Infusate, contaminated, 915
- Inguinal syndrome, 1170
- INH. *See* Isoniazid (INH)
- Inhalational anthrax, 261e-2–3, 784
- Inhaled anesthetics, 54
- Inhibin, 401e-4, 2360, 2378, 2761t
- Inhibitor of apoptosis proteins (IAP), 102e-9,  
 102e-9f
- Inhibitory NK cell receptors (iNKR), in HIV  
 infection, 1238
- Injection drug users  
*Candida* infections in, 836  
 endocarditis in, 816, 817t, 819, 958  
 HIV infection in, 1220t, 1222, 1285  
 sepsis/septic shock in, 1757t  
 tetanus in, 984  
 wound botulism in, 988
- Inkoo virus, 1309t
- Innate immune system, 372e-1, **372e-2**. *See also*  
 Immune response/immune system  
 adaptive immune system and, 372e-2  
 components of, 372e-2, 372e-4t  
 definition of, 372e-1  
 effector cells of, **372e-4**, 372e-7t  
 basophils. *See* Basophil(s)  
 dendritic cells. *See* Dendritic cells  
 eosinophils. *See* Eosinophil(s)  
 macrophages. *See* Macrophage(s)  
 monocytes. *See* Monocyte(s)  
 neutrophils. *See* Neutrophil(s)  
 NK cells. *See* Natural killer (NK) cells  
 primary deficiency of. *See* Primary immune  
 deficiency diseases, of innate immune  
 system  
 PRRs of, 372e-2, 372e-4, 372e-5t
- Inorganic dusts, 1688t, 1691
- Inoue balloon technique, mitral valvotomy,  
 1542f
- Inpatient care, 5
- Inpatient deaths, 55, 56f
- INR (International Normalized Ratio), 405,  
 755
- Insect bites/stings, 341t, 364t, 365, 371, **2748**.  
*See also specific insects*
- Insect-borne disease, prevention of, 796
- Insecticides, 41, 473e-10t
- Insecticide-treated bed nets, 14
- Insertion, gene, 434
- Insomnia  
 assessment of, 65  
 drug-induced, 190  
 etiology of, 65  
 evaluation of, 190  
 fatal familial, 191  
 in medical disorders, 190–191